Bliss GVS Pharma (BOM:506197) Tariff Resilience Score: 0/10 (As of Aug. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:506197 Bliss GVS Pharma Ltd BOM:506197
57 GF Score
Price ₹477.10
GF Value ₹152.44
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Bliss GVS Pharma Tariff Resilience Score?

Bliss GVS Pharma has the Tariff Resilience Score of 0, which implies that the company might have .

Bliss GVS Pharma has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Bliss GVS Pharma might have .

Bliss GVS Pharma  (BOM:506197) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Bliss GVS Pharma Tariff Resilience Score Related Terms

BOM:506197
57GF Score
Bliss GVS Pharma Ltd BOM:506197
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bliss GVS Pharma (BOM:506197) Overvalued in 2026?

Based on GuruFocus' analysis, Bliss GVS Pharma stock appears to be overvalued. The current stock price of ₹477.10 is trading 213% above its estimated GF Value™ of ₹152.44. GuruFocus considers Bliss GVS Pharma to be Significantly Overvalued.

Key valuation signals for BOM:506197:

  • Tariff Resilience Score: 0
  • GF Value™: ₹152.44 vs. price of ₹477.10 (213% above fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the BOM:506197 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bliss GVS Pharma Business Description

Other Exchanges BLISSGVS:India
Address Saki Vihar Road, 102, Hyde Park, Andheri (East), Mumbai, MH, IND, 400072
Bliss GVS Pharma Ltd is an India-based company engaged in the manufacturing, marketing, trading, and export of pharmaceutical products. Some of its brands include Lonart, P-Alaxin, Funbact, and Lofnac, and others. It offers pharma products including tablets, suspensions, suppositories, and injections. The majority of its revenue is derived from Exports.
57GF Score

Get the complete analysis for BOM:506197

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹477.10
Price
₹152.44
GF Value